Drugs.com - Clinical Trials

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple...

Apr 10, 2025 - 23:37
 0
Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis
Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple...
Read More

Tags:

Previous Article

[Comment] Broken promises: the USA foreign aid freeze threatens women's, childre...

Next Article

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Compl...

Related Posts

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Investigational Rinatabart Sesutecan (Rina-S®) Continue...

Mar 19, 2025  0

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan ...

Mar 26, 2025  0

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025  0